Lindbrook Capital LLC Purchases 95 Shares of Laboratory Co. of America Holdings (NYSE:LH)

Lindbrook Capital LLC grew its position in Laboratory Co. of America Holdings (NYSE:LH) by 11.2% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 946 shares of the medical research company’s stock after acquiring an additional 95 shares during the period. Lindbrook Capital LLC’s holdings in Laboratory Co. of America were worth $215,000 at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. Raymond James Financial Services Advisors Inc. raised its stake in Laboratory Co. of America by 5.1% in the third quarter. Raymond James Financial Services Advisors Inc. now owns 25,354 shares of the medical research company’s stock valued at $5,097,000 after buying an additional 1,237 shares during the period. Daiwa Securities Group Inc. lifted its holdings in Laboratory Co. of America by 6.0% during the 3rd quarter. Daiwa Securities Group Inc. now owns 8,509 shares of the medical research company’s stock valued at $1,711,000 after purchasing an additional 484 shares during the last quarter. Handelsinvest Investeringsforvaltning bought a new position in Laboratory Co. of America during the fourth quarter worth $1,091,000. Cerity Partners LLC increased its holdings in shares of Laboratory Co. of America by 8.6% in the fourth quarter. Cerity Partners LLC now owns 64,435 shares of the medical research company’s stock valued at $14,645,000 after purchasing an additional 5,105 shares during the last quarter. Finally, Salem Investment Counselors Inc. raised its position in shares of Laboratory Co. of America by 202.4% in the fourth quarter. Salem Investment Counselors Inc. now owns 9,243 shares of the medical research company’s stock valued at $2,101,000 after purchasing an additional 6,186 shares during the period. 95.94% of the stock is currently owned by institutional investors and hedge funds.

Laboratory Co. of America Stock Performance

NYSE LH opened at $203.07 on Tuesday. Laboratory Co. of America Holdings has a 1 year low of $174.20 and a 1 year high of $234.09. The firm has a market capitalization of $17.08 billion, a price-to-earnings ratio of 43.48, a P/E/G ratio of 1.51 and a beta of 1.01. The company has a current ratio of 1.17, a quick ratio of 1.02 and a debt-to-equity ratio of 0.52. The firm’s 50 day simple moving average is $213.25 and its 200 day simple moving average is $214.81.

Laboratory Co. of America (NYSE:LH) last issued its quarterly earnings results on Thursday, February 15th. The medical research company reported $3.30 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.29 by $0.01. Laboratory Co. of America had a return on equity of 13.99% and a net margin of 3.24%. The company had revenue of $3.03 billion for the quarter, compared to analyst estimates of $3.02 billion. During the same quarter last year, the company posted $4.14 EPS. The company’s revenue for the quarter was down 17.5% compared to the same quarter last year. As a group, research analysts expect that Laboratory Co. of America Holdings will post 14.84 earnings per share for the current fiscal year.

Laboratory Co. of America Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, June 12th. Stockholders of record on Tuesday, May 28th will be issued a $0.72 dividend. The ex-dividend date is Friday, May 24th. This represents a $2.88 dividend on an annualized basis and a dividend yield of 1.42%. Laboratory Co. of America’s dividend payout ratio (DPR) is currently 61.67%.

Insider Activity

In related news, COO Mark S. Schroeder sold 5,048 shares of the stock in a transaction that occurred on Thursday, March 7th. The shares were sold at an average price of $218.45, for a total value of $1,102,735.60. Following the completion of the transaction, the chief operating officer now owns 5,036 shares of the company’s stock, valued at approximately $1,100,114.20. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. In related news, COO Mark S. Schroeder sold 5,048 shares of the business’s stock in a transaction on Thursday, March 7th. The stock was sold at an average price of $218.45, for a total transaction of $1,102,735.60. Following the sale, the chief operating officer now owns 5,036 shares in the company, valued at approximately $1,100,114.20. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Glenn A. Eisenberg sold 34,504 shares of the stock in a transaction dated Wednesday, February 21st. The shares were sold at an average price of $215.97, for a total value of $7,451,828.88. Following the completion of the transaction, the chief financial officer now owns 23,595 shares of the company’s stock, valued at $5,095,812.15. The disclosure for this sale can be found here. In the last three months, insiders have sold 54,305 shares of company stock worth $11,761,059. Corporate insiders own 0.85% of the company’s stock.

Wall Street Analyst Weigh In

LH has been the topic of a number of research reports. Evercore ISI initiated coverage on shares of Laboratory Co. of America in a research note on Friday, February 9th. They issued an “in-line” rating and a $240.00 price target on the stock. Barclays assumed coverage on Laboratory Co. of America in a research report on Wednesday, January 3rd. They issued an “equal weight” rating and a $222.00 target price on the stock. Leerink Partnrs restated an “outperform” rating on shares of Laboratory Co. of America in a research note on Monday, February 26th. SVB Leerink assumed coverage on Laboratory Co. of America in a research report on Monday, February 26th. They set an “outperform” rating and a $260.00 price objective on the stock. Finally, Argus raised Laboratory Co. of America from a “hold” rating to a “buy” rating and set a $250.00 target price for the company in a report on Monday, March 25th. Four investment analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $243.50.

Laboratory Co. of America Profile

Laboratory Corporation of America Holdings operates as a life sciences company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. It operates in two segments, Labcorp Diagnostics (Dx) and Biopharma Laboratory Services (BLS).